– CANADA, Mississauga – Evolve Biologics Inc., an innovative plasma-derived therapeutics company, today announced the appointment of Jim Caggiano as CEO.
Mr. Caggiano’s nearly 30 years of experience, bringing life-saving products to the market in the biotech, pharma, and medical device industries will help accelerate the commercialization of the company’s PlasmaCap EBA technology, which stands to disrupt the global plasma-derived therapeutics market with its high-quality product yields at improved levels of efficiency and reliability compared to currently available technologies.
“We’re excited to welcome Jim Caggiano to the Evolve team. His leadership and track record delivering the critical regulatory, manufacturing, and distribution components required to bring life-saving therapies to market will be invaluable as we move forward to serve and technologically disrupt the large and growing $24 billion global plasma-derived therapeutics market, with our proprietary PlasmaCap EBA.” said Board Chairman, Gabriel de Alba.
Mr. Caggiano joins the company’s proven leadership team of David Holliday, Chief Commercial Officer, and Mark Krause, Head of Plasma Proteins.
Mr. Caggiano added, “With the demand for some critical plasma-derived therapeutics, including IVIG, often outstripping global supply in the past, PlasmaCap EBA technology is a game-changer, with its impressive yields and efficiencies relative to current legacy processes. As we advance to the final stages to bring IVIG to market, I’m thrilled by this opportunity to join the highly accomplished Evolve team, whose work over the past eight years has laid the technology foundations for PlasmaCap EBA, while advancing IVIG through the completion of Phase III trials.”
About Jim Caggiano
Jim Caggiano joins Evolve Biologics as CEO, after most recently serving as CEO of Dendreon Pharmaceuticals LLC. Among his earlier leadership roles in the biotech, pharmaceutical, and medical device industries, Mr. Caggiano successfully directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013. In 2015, he was hired by Valeant to run the Dendreon business, where he doubled the company’s enterprise value. He then developed and implemented the strategy for Dendreon’s sale in 2017 to Sanpower Group for $820M, who subsequently appointed him CEO, where he led the previously bankrupt enterprise to achieve over $100 million in EBITDA in 2018 and 2019. Earlier in his career, Mr. Caggiano held senior roles at Allergan, Inc., Abbott Laboratories, and TAP Pharmaceuticals, where he led sales and marketing functions for Lupron, a prostate cancer treatment.
Mr. Caggiano received a B.S. in agricultural economics from Cornell University and an M.B.A. from the Kellogg School of Management at Northwestern University. Before entering the industry, Mr. Caggiano served as an officer in the Armor Branch of the United States Army.
About Evolve Biologics Inc.
Evolve Biologics Inc. is a leader in the development and commercialization of plasma-derived therapeutics, using its proprietary PlasmaCap EBA purification technology to more efficiently and effectively meet growing global patient demand for these life-saving products. The Company is currently in the process of commercializing an exciting and innovative portfolio of product candidates, including IVIG and Albumin, both of which are in advanced stages of regulatory approval in the US and Canada. The Company is headquartered in Mississauga, Ontario, Canada.
For more information: https://www.evolvebiologics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.